Physician profile
Mitchell D Jacobs
NPI 1841556636
$9,820.91
in general payments reported to CMS, 2019-2025
30 companies · $4,046 in 2025
The $4,046 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $442 · 2021: $333 · 2022: $716 · 2023: $735 · 2024: $2,884 · 2025: $4,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,517 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,516.96 |
| Education | $148.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,508.84 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $2,409.05 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Jazz Pharmaceuticals INC. | $869.30 | 2019-2025 | Xywav |
| Harmony Biosciences LLC | $518.40 | 2024-2025 | |
| Insmed, INC. | $478.81 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $380.93 | 2019-2025 | |
| Axsome Therapeutics, INC. | $318.46 | 2024-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $304.85 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.22 | 2020-2025 | Ofev, Jascayd |
| Verona Pharma, INC. | $285.53 | 2025 | Ohtuvayre |
| Amgen INC. | $235.62 | 2021-2025 | Tezspire, Tavneos |
| Mylan Specialty L.P. | $132.52 | 2020-2023 | Yupelri |
| Pulmonx Corporation | $116.66 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Mallinckrodt Hospital Products INC. | $107.24 | 2024-2025 | Acthar |
| Electromed, INC. | $104.93 | 2024-2025 | Smartvest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| United Therapeutics Corporation | $87.67 | 2024-2025 | Tyvaso, Tyvaso |
| Avadel Cns Pharmaceuticals, LLC | $82.10 | 2024-2025 | Lumryz |
| Philips North America LLC | $74.23 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Genentech USA, INC. | $72.86 | 2021-2024 | Xolair |
| Inspire Medical Systems, INC. | $62.58 | 2025 | Inspire |
| Baxter Healthcare | $59.29 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Novartis Pharmaceuticals Corporation | $39.65 | 2019 | |
| Paratek Pharmaceuticals, INC. | $37.57 | 2024 | Nuzyra |
| Grifols USA, LLC | $32.68 | 2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $30.37 | 2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $22.26 | 2025 | Opsumit, Uptravi |
| Resmed Corp | $17.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.47 | 2022 | |
| Advanced Respiratory, INC | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.